Medical device company SI-Bone delivered impressive second-quarter 2025 financial results, presenting investors with a complex picture of robust operational performance alongside notable selling activity from both institutional and internal stakeholders.
Financial Performance Highlights
The company achieved global revenue of $48.6 million, representing a substantial 21.7% increase compared to the same period last year. U.S. market performance was particularly strong, climbing 22.8% to reach $46.4 million, driven by heightened demand for the company’s sacropelvic solutions. Gross margins expanded significantly to 79.8%.
Despite reporting a quarterly net loss of $6.2 million, SI-Bone showed considerable improvement with a 31.2% reduction in losses year-over-year. The company reached a critical milestone by achieving positive adjusted EBITDA for the first time, which came in at $1.0 million. Based on this strong quarterly showing, management raised its full-year 2025 revenue guidance to a range of $195 to $198 million.
Should investors sell immediately? Or is it worth buying SI-Bone?
Ownership Dynamics and Trading Activity
Institutional investors maintain overwhelming control with 98.11% of outstanding shares, typically indicating broad market confidence. However, recent transactions reveal some shifting positions:
- Deutsche Bank AG reduced its SI-Bone holdings by 10.2% during the first quarter of 2025, disposing of 3,685 shares
- Chief Executive Officer Laura Francis sold 11,343 shares on August 18 at an average price of $15.60, totaling approximately $176,950
Market Sentiment and Future Catalysts
Equity researchers maintain a cautiously optimistic stance, with consensus price targets averaging $23.67, suggesting potential upside from current trading levels. Recommendations remain mixed, spanning both “Buy” and “Hold” ratings.
Market participants are watching for potential catalysts, including the company’s scheduled appearance at the Morgan Stanley Global Healthcare Conference on September 9. Management is set to participate in a fireside chat format discussion, where they will provide insights into strategic initiatives and market opportunities within the sacropelvic treatment landscape.
Ad
SI-Bone Stock: Buy or Sell?! New SI-Bone Analysis from January 13 delivers the answer:
The latest SI-Bone figures speak for themselves: Urgent action needed for SI-Bone investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 13.
SI-Bone: Buy or sell? Read more here...
